ReviewJBMR plus2025
Muscle impairments in osteogenesis imperfecta: a narrative review.
Review in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Macrophage regulation of extracellular matrix remodeling in aging skeletal muscle.Ageing research reviews · 2026Review
- Dose matters: haploinsufficiency in osteogenesis imperfecta.Nature reviews. Endocrinology · 2026Review
- Transcriptional profiling of otic capsule and femur in the oim mouse model of osteogenesis imperfecta.JBMR plus · 2026Article
- OMICS Profiling Identifies Signatures of Senescence in Osteogenesis Imperfecta Osteoblasts Counteracted by 4-PBA.Journal of cellular and molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this review is to provide an overview of the available evidence on the effects of OI on skeletal muscle. This encompasses multiple components of muscle function, underlying biological and environmental factors, clinical and functional consequences, and relevant epidemiology and therapeutic options. OI is a rare connective tissue disorder causing bone fragility and skeletal deformity, and extraskeletal features, including cardiac and dental abnormalities and hearing loss. The condition is also characterized by pronounced deficits in multiple aspects of skeletal muscle function, including lower muscle strength and power, impaired balance, and greater fatigability, resulting from lower muscle mass and poor muscle quality. These deficits have important implications for multiple aspects of health and general function, including mobility, fall and fracture risk, and the ability to carry out activities of daily living. The muscle weakness and impaired function in OI appear multi-factorial in origin, and factors including deficits in sensory, ventilatory, and metabolic function may compound those observed in muscle mass and quality. Little is known about the epidemiology of muscle in OI, with the exception that more severe OI types are associated with greater impairments in function and mass. Consideration should be given to which aspects of muscle health and function are most relevant for individuals with different OI types. There is a limited evidence base for interventions to improve muscle in OI, and current findings from physical activity and pharmacological therapies are mixed. Muscle represents an important and under-researched area of health and function in OI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.